Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Director · Chief Executive Officer | August 27, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tonix Pharmaceuticals Holding Corp.
Report date August 27, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy IRA Account | 11,005 |
Reported balance
After 2026-08-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-27 · Purchase · Acquired 2,000 · Balance 11,005 F1: Reporting person may be deemed a control person of this entity. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 20,001 |
Reported balance
Holding disclosure · report date 2026-08-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,001 |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectLederman & Co. | 1 |
Reported balance
Holding disclosure · report date 2026-08-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1 F1: Reporting person may be deemed a control person of this entity. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person may be deemed a control person of this entity.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2018 Filed Feb 15, 2018 21:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 156,601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001615774-18-001263 · s109082_form4.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,601 Underlying: Common Stock · 156,601 shares Expires 2028-02-12 F2 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| December 26, 2017 Filed Dec 27, 2017 19:04 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 5,300 | $3.61 | $19,133.00 |
DisclosureSEC source: 0001615774-17-007619 · s108549_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) plan Disclosed balance after: 22,700 F1 · price: The volume weighted average purchase price of common stock purchased by the reporting person in open market transactions on the transaction date. The range of purchase prices on the transaction date was $3.5834 to $3.619 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| August 17, 2017 Filed Aug 18, 2017 19:40 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 15,000 | $3.00 | $45,067.50 |
DisclosureSEC source: 0001615774-17-004563 · s107264_form4.xml · nonDerivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA account Disclosed balance after: 50,000 Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 19:40 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 5,000 | $2.99 | $14,950.00 |
DisclosureSEC source: 0001615774-17-004563 · s107264_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA account Disclosed balance after: 35,000 Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 21:38 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 5,000 | $4.33 | $21,640.00 |
DisclosureSEC source: 0001615774-17-003457 · s106735_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA account Disclosed balance after: 30,000 F1 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.32797964. The range of purchase prices on the transaction date was $4.3123 to $4.35 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| June 26, 2017 Filed Jun 26, 2017 21:29 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 5,000 | $4.40 | $21,999.50 |
DisclosureSEC source: 0001615774-17-003376 · s106692_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA account Disclosed balance after: 25,000 Read SEC document |
| June 20, 2017 Filed Jun 20, 2017 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 20,000 | $4.22 | $84,400.00 |
DisclosureSEC source: 0001615774-17-003262 · s106604_lederman.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA account Disclosed balance after: 20,000 F1 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.220019425. The range of purchase prices on the transaction date was $4.13 to $4.25 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 02:24 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 160,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001615774-17-000860 · s105459_form4.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2027-03-01 F2 · price: The option was granted pursuant to the Issuer's 2016 Stock Incentive Plan. F3 · derivative.exercise_date: The option vests 50% if the Issuer achieves enrollment of 250 patients in its HONOR study by December 31, 2017, with the remaining 50% vesting 1% for each patient that is enrolled in the HONOR study by December 31, 2017 in excess of 250, subject to a one year minimum service period prior to vesting. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 02:24 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 160,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001615774-17-000860 · s105459_form4.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2027-03-01 F2 · price: The option was granted pursuant to the Issuer's 2016 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 21:23 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 98,000 | $0.43 | $41,924.40 |
DisclosureSEC source: 0001615774-16-008539 · s104774_lederman.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) plan Disclosed balance after: 133,000 F1 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.427821. The range of purchase prices on the transaction date was $0.4191 to $0.4299 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:37 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock Purchase Warrant · Derivative | 10,000 | Not disclosed Strike: $0.63 | Not disclosed |
DisclosureSEC source: 0001615774-16-007912 · s104485_form4.xml · derivative · entry 9 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2021-10-31 F1 · price: Included in the purchase of 10,000 Units at a price of $0.55 per Unit. Each Unit consisted of one share of common stock and one warrant exercisable immediately for one-half (0.50) share of common stock at an exercise price of $0.63 per share. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:37 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001615774-16-007912 · s104485_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,815 F1 · price: Included in the purchase of 10,000 Units at a price of $0.55 per Unit. Each Unit consisted of one share of common stock and one warrant exercisable immediately for one-half (0.50) share of common stock at an exercise price of $0.63 per share. Read SEC document |
| June 30, 2016 Filed Feb 13, 2017 11:06 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock | 3,296 | $1.74 | $5,735.04 |
DisclosureSEC source: 0001615774-17-000513 · s105310_form5.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,111 F1 · kind: Shares acquired through the Tonix Pharmaceuticals Holding Corp. Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.